Seeking Alpha
0
All posts from Seeking Alpha
Seeking Alpha in Seeking Alpha - Read, Decide, Invest.,

Update: ETC-1002 Development Remains On Track

After the market close on Monday, Esperion Therapeutics (NASDAQ:ESPR) announced that the FDA has removed the peroxisome proliferator-activated receptor (PPAR) partial clinical hold on ETC-1002. This is a significant step in the development of ETC-1002, as it allows the company to conduct clinical trials exceeding 6 months, which keeps the Phase 3 trials on schedule to begin in Q4…